Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access...
-
SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm...
-
First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of...
-
SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax...
-
SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will...
-
SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the American Society for...
-
At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target...
-
SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred...
-
SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its...
-
Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin...